New home for bromodomains

Researchers at the Dana-Farber Cancer Institute and the Baylor College of Medicine have shown that Tensha Therapeutics Inc.'s bromodomain inhibitors could prevent sperm production and be developed as a male contraceptive.1 The biotech, which is focused on developing the molecules for cancer, has exclusive rights to the findings and is interested in pursuing bromodomain inhibitors in the indication.

Available options for male contraception are limited to barrier methods and vasectomy. There are no male contraceptive drugs on the market. Several hormone-based strategies are in the clinic but carry the risk of systemic side effects.

Indeed, Michael O'Rand, professor of cell biology and developmental biology at The University of North Carolina at Chapel Hill, said not all men react the same way to testosterone-based contraceptives and that testosterone can cause increased

Read the full 1280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers